Stock screenerAll disclosures →
EDGAR →
RXRX
Conviction 6HealthcareScan · Mon, Jul 20, 2026RXRX$2.88-2.21%
ResistanceSupportVol 14Insider sell2
Vol MA14 27.58M
Apr 20May 6May 26Jun 11Jul 1Jul 20
Price2.88
Change-2.21%
Gap+0.00%
Rel volume1.31×
Avg volume25.42M
Avg $ vol88.28M
SMA 203.44
SMA 503.31
SMA 2004.02
Price vs 50-13.03%
Price vs 200-28.38%
MA stackbearish
50/200 cross—
Supertrenddown · 3.58
RSI (14)34
MACD hist-0.10
MACD crossbear · 5d
Stoch %K / %D3 / 3
ADX (14)21
+DI / −DI20 / 30
RSI divergence—
MACD divergence—
ATR %+8.16%
ADR %6.66%
52w high6.79
52w low2.84
From 52w high-57.58%
Above 52w low+1.41%
New 52w highNo
SqueezeOff
Bollinger width35.89%
%B0.04
Donchian pos2.81%
Donchian high4.09
Donchian low2.85
AVWAP (52w high)4.16
vs AVWAP high-30.82%
AVWAP (52w low)3.40
vs AVWAP low-15.26%
OBV trendFlat
Chaikin MF (20)-0.17
Today vs 20d1.31×
Avg vol (14d)27.58M
Avg vol (20d)25.42M
Avg $ vol (20d)88.28M
Market cap484.76M
RS 3m (vs SPY)-24.13%
RS 6m (vs SPY)-46.95%
RS line new highNo
Trend template0/8
Technical rank11.3
1 week-12.73%
1 month-7.40%
3 months-23.81%
6 months-37.93%
1 year-47.83%
YTD-31.43%
P/E-0.75
P/B0.47
P/S6.49
P/FCF-1.28
EPS-1.44
Div yield—
ROE-62.92%
ROA-48.13%
Debt/Eq0.00
Current5.47
EV/EBITDA0.30
Gross margin—
Net margin-863.35%
Rev growth26.92%
EPS growth-39.06%
Price target7.38
Target upside156.25%
Analyst ratingHold
Institutional76.80%
Ent. value-168.99M
Revenue6.47M
Net income-117.5M
Gross profit—
Free cash flow-378.28M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out524.68M
Employees600
ListedFri, Apr 16, 2021
Free float409.84M
Float %78.5%
Short interest172.3M
Days to cover8.4d
Short volume61.8%
Squeeze score84 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.22 vs −$0.30
Last surprise+26.7% beat
Setup gradeD
Conviction6 / 100
Pattern quality—
Tech rank11.3 / 100
Group rank23 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance4.07
Support2.93
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in RXRX
No recent disclosed trades by Congress in RXRX. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in RXRX · 7 buys · 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Borgeson Blake Director · Class A Common Stock · 2026-07-07 | Sell | 40K | $159K | 2026-07-07 | 2026-07-09 |
Bumpus Namandje Director · Class A Common Stock · 2026-06-18 | Sell | 3.96K | $13K | 2026-06-18 | 2026-06-22 |
Li Dean Y Director · Class A Common Stock · 2026-06-17 | Grant | 88.42K | — | 2026-06-17 | 2026-06-22 |
Bumpus Namandje Director · Class A Common Stock · 2026-06-17 | Grant | 88.42K | — | 2026-06-17 | 2026-06-22 |
Borgeson Blake Director · Class A Common Stock · 2026-06-17 | Grant | 88.42K | — | 2026-06-17 | 2026-06-22 |
HERSHBERG ROBERT Director · Class A Common Stock · 2026-06-17 | Grant | 88.42K | — | 2026-06-17 | 2026-06-22 |
Dar Zavain Director · Class A Common Stock · 2026-06-17 | Grant | 88.42K | — | 2026-06-17 | 2026-06-22 |
Michor Franziska Director · Class A Common Stock · 2026-06-17 | Grant | 88.42K | — | 2026-06-17 | 2026-06-22 |
Sun Elaine D Director · Class A Common Stock · 2026-06-17 | Grant | 88.42K | — | 2026-06-17 | 2026-06-22 |
Gibson Christopher Director · Stock Option (Right to Buy) · 2026-06-05 | Other | — | — | 2026-06-05 | 2026-06-05 |
SEC filings
EDGAR filings in RXRX · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.